Pfizer, BioNTech start trial for first mRNA-based shingles vaccine (NYSE:PFE) | Seeking Alpha

Pfizer (PFE) and BioNTech (BNTX) announced Friday the start of a Phase 1/2 trial for the companies' mRNA vaccine candidates against shingles. Read the full story here.